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INTRODUCTION 
Hepatocellular carcinoma (HCC) is the second leading cause of 
cancer related deaths and accounts for 65% of all liver cancers.1-3 
The SEER-Medicare database estimated a significant annual eco-
nomic burden from HCC between 1991 and 1999 of 454.9 million 
US dollars.4 Surprisingly, the incidence of HCC has increased from 
1.4/100,000 cases between 1976-1980 to 6.2/100,000 cases in 
2011.3 The increased incidence of HCC in the United States has 
promoted the use of catheter based, image guided therapies, in-
cluding trans arterial chemoembolization (TACE) with convention-
al trans-arterial chemotherapy or specifically doxorubicin (cTACE), 
using drug-eluting beads with chemotherapeutic agents (DEB-
TACE), bland embolization (TAE) and radioembolization or selec-
tive internal radiation therapy (SIRT) with Yttrium 90 (90Y) micro-
spheres. Loco-regional techniques reduce patient morbidity, 
reduce mortality, can be used repeatedly and are associated with 
increased survival.5 Advancement of these techniques and devel-
opment of other novel approaches to disease management remain 
the focus of current laboratory based and clinical research.
Liver transplantation and resection are the only curative options 
for patients with HCC or colorectal cancer metastases, limited pri-
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marily by the high demand and low supply of organ donation. 
Fewer than 20% of patients are candidates for resection due to 
tumor size (>3 cm), unresectable anatomical locations, undesir-
able number or distribution of tumors, extrahepatic involvement, 
and low healthy tissue reserve due to cirrhosis and other co-mor-
bidities.6 Unfortunately, the median survival for patients with HCC 
is less than a year without treatment, and increases greatly with 
surgical resection or transplantation. However, even in HCC pa-
tients who do undergo resection, recurrence rates are as high as 
70% at 5 years7, therefore development of more consistent and 
effective treatment methods for unresectable liver cancer patients 
is crucial.
There is no clinically proven current standard for treatment for 
patients with unresectable HCC.7 In this paper, we present four 
different transarterial therapies including TACE with drug-eluting 
beads (DEB-TACE), transarterial embolization (TAE) or bland em-
bolization and radioembolization or SIRT using 90Y microspheres. 
These techniques are generally accepted as effective palliative 
treatment and are increasingly being utilized to downstage tu-
mors prior to surgery and to prolong survival. In addition, we plan 
to briefly discuss recent chemotherapeutic agents including Beva-
cizumab (Avastin®) and Panitumumab (Vectibix®). 
cTACE
In the early 1970’s, angiographers first experimented with em-
bolization agents during angiographic procedures to treat liver tu-
mors with palliative effects.8 Over the years the technique has 
evolved to now treat unresectable HCC, colorectal liver metasta-
ses, neuroendocrine liver metastases, cholangiocarcinoma, ocular 
melanoma, and metastatic sarcoma.5,6 TACE involves the catheter-
Table 1. Summary of evidence for transarterial chemoembolization (TACE)
Authors n Summary
TACE (conventional) Solomon, et al.11 
(1999)
  38 Cisplatin, doxorubicin, mitomycin-C, ethiodol, polyvinyl alcohol.
Biologic response: 70% partial, 15% minor, 15% stable
Morphologic response: 36% partial, 32% minor, 32% stable
Lo, et al.12 (2002)   40 Cisplatin, lipiodol, gelatin sponge particles vs symptomatic treatment
Increased survival in chemoembolization group 1 year 57%, 2 years 31%, 3 years 26% vs 
control 1 year 32%, 2 years 11%, 3 years 3% (P 0.002)
Marelli, et al.13 
(2007)
175 Meta-analysis of single, double or triple agent transarterial chemotherapies
Objective response 40 +/- 20%
Survival rates at 1,2,3,5 years of 62 +/- 20%, 42 +/- 17%, 30 +/- 15%, 19 +/- 16%. 
Survival time 18 +/- 9.5 months
Llovet, et al.14  
(2003)
545 Meta-analysis of TACE vs tamoxifen
Survival benefit with cisplatin/doxorubicin OR 0.42, 95% CI 0.2-0.88). No survival benefit with 
embolization alone OR 0.59, 95% CI, 0.29-1.20). Tamoxifen showed no antitumoral effect or 
survival benefit (OR 0.64, 95% CI 0.36-1.13, P=0.13)
TACE (doxorubicin) Lammer, et al.19 
(2010)
212 TACE with doxorubicin loaded on drug eluting beads loaded or TACE with doxorubicin oil 
emulsion and gelatin sponge.
Higher complete response (27% vs 22%), objective response (52% vs 44%), disease control 
(63% vs 42%) (P=0.11). 
Significant increase in objective response of patients who received drug eluting beads and 
had Child-Pugh B, ECOG 1, bilobar disease and recurrent disease (P=0.038)
Drug eluting beads associated with lower serious liver toxicity (P<0.001) and less doxorubicin 
related side effects (P=0.0001). 
Golfieri, et al.20 
(2014)
177 Doxorubicin loaded drug eluting bead TACE vs conventional TACE
No difference in survival, local or overall tumor response or median time to progression 
between the two groups. 
Post procedural pain more frequent and severe after cTACE (P<0.001). 
ECOG, serum albumin and tumor number independently predicted survival (P<0.05). 
Facciorusso, et 
al.21 (2016)
676 Meta-analysis of transarterial chemoembolization vs bland embolization 
No difference in 1 year, 2 year or 3 year survival (P=0.16, 0.18, 0.81)
No difference in objective response and one year progression free survival (P=0.36, P=0.40). 
Significant increase in severe toxicity after chemoembolization (P=0.01). 
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based delivery of various chemotherapeutic drugs to the arteries 
supplying the tumor, combined with the delivery of embolic mate-
rial for containment and reduction of arterial inflow, which pro-
longs the duration of contact of the chemotherapeutic agent with 
the tumor. Hypervascularized tumors are predominantly supplied 
by the hepatic artery whereas normal liver parenchyma is typically 
supplied by the portal vein, therefore this method of targeting the 
hepatic artery allows healthy liver tissue to be spared.5
Although various chemotherapeutic agents are used in TACE, 
the most commonly used single agent is doxorubicin.9 A combina-
tion of cisplatin, doxorubicin and mitomycin C has been also fa-
vorable amongst the interventional radiology community. Ethiodol 
is used as an emulsifying agent with preferential ability to bind to 
tumor cells, deliver chemotherapeutic agents, and cause ischemia 
through embolization and vascular occlusion. A variety of several 
other embolic materials are also used with TACE, including Gel-
foam, microspheres (Embozene® and Embospheres®), and 
polyvinyl alcohol (PVA) particles.5 Gelfoam is indicated for tempo-
rary vascular occlusion where recanalization is desired after a 
short duration, for example to temporarily occlude a shunt.  Mi-
crospheres and PVA particles are indicated for more permanent 
vascular occlusion. The selection and advantage of each embolic 
agent remain controversial and operator dependent. Overall, em-
bolization allows for up to a two-fold increase in peri-tumoral 
drug concentration, decreased systemic toxicity, increased tumor 
destruction and decreased drug resistance via stasis and ischemia. 
The maintenance of arterial patency is imperative, as multiple se-
quential treatments of cTACE are commonly performed and may 
increase patient survival. Tumor size and perfusion status is evalu-
ated on imaging studies every 4 to 12 weeks to evaluate response 
to treatment.6
cTACE FOR HCC 
Despite persuasive clinical results from cTACE, the evidence for 
clinical efficacy has not yet been well assessed in randomized 
clinical trials. Numerous studies have been published and multiple 
clinical trials are being conducted or in process of completion (ap-
proximately 191 clinical trials worldwide at the time of publica-
tion10), however interpretation of the results has been challenging 
for several reasons.  Firstly, the measure of treatment success of 
cTACE in HCC is attributed to many factors, without standardiza-
tion to provide uniform comparison of the data among the current 
studies. Secondly, with the use of numerous staging systems, in-
clusion criteria and exclusion criteria, there is increased difficulty 
in comparison of different centers. Interestingly, patient survival is 
the most commonly cited and relevant outcome measure in stud-
ies, despite the short life expectancy of HCC patients. 
Aside from the lack of evidence supporting the clinical efficacy 
of cTACE, it has maintained its status as a robust therapeutic op-
tion throughout the years, mainly due to clinical expertise and 
paucity of good alternatives for unresectable HCC. Prospective 
non-randomized trials in the United States also show survival data 
comparable to the latest randomized controlled trials performed 
in other countries.11 
A randomized controlled trial performed in 2002 in Hong Kong 
and demonstrated that cTACE (with cisplatin, lipiodol and 
gelfoam)-treated patients have significantly better survival than a 
control group (1 year, 57% vs. 32%; 2 years, 31% vs. 11%; 3 
years, 26% vs. 3%.12 A European study involving 75 patients also 
showed improved survival of TACE over symptomatic treatment (1 
year, 82% vs. 63%; 2 years, 63% vs. 27%; 3 years, 29% vs. 
17%.13 The patients enrolled in both these studies were comprised 
of patients with intermediate tumor stage and preserved liver 
Table 2. Summary of evidence of bland transarterial embolization (TAE) 
Authors n Summary
Kluger, et al.23 (2014)   25 TACE vs TAE prior to transplantation
TAE patients were less likely than TACE patients to require 2 procedures (P=0.04)
Explant tumors were completely necrotic for 36% of TAE patients, 26% of TACE patients
3 year survival was higher for TAE (78%) than TACE (74%), (P=0.66)
3 year recurrence free survival rates was TAE (72%) and TACE (68%), P=0.83
Massarweh, et al.24 (2016) 405 TAE vs TACE
No significant difference in mean survival (20.1 vs 23.1 months, P=0.84)
No significant difference in risk of death associated with TAE. 
Brown, et al.25 (2016) 101 Embolization with microspheres alone vs Doxorubicin-Eluting Microspheres
Similar adverse events in both groups (38% vs 40%, P=0.48)
No significant difference in RECIST response, median progression free survival and overall survival. 
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function (Child-Pugh class A). Despite the difference in patient 
populations (Asian patients with hepatitis B or European patients 
with hepatitis C), similar results from both studies are very en-
couraging. Furthermore, similarity in survival was found between 
treated and non-treated patients in the United States through co-
hort studies. One such study of 38 TACE-treated patients by Solo-
mon, et al.11 showed survival rates of 1 year, 60%; 2 years, 45%; 
and 3 years, 16%. A meta-analysis of all cohort studies since 
2000—including Western studies—show comparable survival 
rates of 1 year, 71%; 2 years, 48%; 3 years, 34%.13 cTACE shows 
a significant survival advantage when compared with systemic 
chemotherapy for HCC patients. The meta-analysis by Llovet, et 
al. showed an odds ratio of 0.53 in 2-year survival when com-
pared with systemic tamoxifen.14 
cTACE is typically well-tolerated, however serious complications 
occur at a mean rate of 5.6% and include acute liver failure, ab-
scess and sepsis, and gastrointestinal bleeding.15 Mortality directly 
related to cTACE is less than 4%, with 30-day mortality of 1%.6,15 
The most common complication is a 7-10 day long post-emboliza-
tion syndrome including nausea, vomiting, fever, and abdominal 
pain (Table 1).6
DEB-TACE
In order to achieve more sustained levels of chemotherapy con-
centrated in the tumor, an embolic product, which gradually re-
leases the drug over time, has been developed so-called drug-
Table 3. Summary of evidence for radioembolization (90Y)
Authors n Summary
Salem, et al.32 (2005) 43 90Y for unresectable hepatocellular carcinoma: safety, tumor reponse and survival in segmental, lobar low 
risk and lobar high risk groups, Okuda and Childs-pugh scoring systems.
47% objective tumor response based on percent reduction in tumor size
79% tumor response based on percent reduction and/or tumor necrosis as a composite measure
Significant difference in survival in segmental (46.5months), lobar low risk (16.9 months), lobar high risk (11.1 
months) (P<0.0001)
No significant difference in tumor response between segmental, lobar low risk and lobar high risk groups.
Median survival of Okuda I (24.4 months), Okuda II (12.5 months), Childs A (20.5 months), Childs B/C (13.8 
months). 
Lau, et al.36 (1998) 71 Intraarterial infusion of 90Y microspheres for non resectable hepatocellular carcinoma
50% reduction in tumor volume in 26.7% patients after first treatment
Partial response 67%, complete response 22%, in patients with elevated AFP.
Decrease in serum ferritin by 34-99% after treatment, in pateints without elevated AFP. 
Median survival 9.4 months, range 1.8-46.4 months
Kulik, et al.37 (2006) 150 90Y for unresectable hepatocellular carcinoma: downstaging to resection, RFA, bridge to transplantation. 
56% were downstaged from UNOS T3 to T2 after treatment
32% were downstaged to target lesions <3.0 cm 
66% were downstaged to UNOS T2, lesion <3.0 cm (RFA candidate) or resection. 
50% had an objective tumor response by WHO criteria
23% were downstaged and underwent OLT after treatment. 
1,2 and 3 year survival was 84%, 54% and 27%. 
Median survival for entire cohort = 800 days. 
Salem, et al.30 (2016) 179 90Y vs conventional TACE
Significantly longer median time to progression in Y90 patients than cTACE patients (>26 months, 6.8 
months, P=0.0012)
TACE group had significantly higher diarrhea (21% vs 0%, P=0.031), hypoalbuminemia (58% vs 4%, P<0.001). 
Similar response to therapy, marked by necrosis in both groups (P=0.433)
Median survival time, censored to liver transplantation was 17.7 months for TACE group vs 18.6 months for 
90Y group (P=0.99) 
Lobo, et al.40 (2016) 533 Systematic review and meta-analysis of radioembolization (TARE) vs chemoembolization (TACE)
No significant difference in survival up to 4 years between the two groups (P=0.567)
TACE had more post treatment pain than TARE (P<0.01), less subjective fatigue (P<0.01). 
No difference between the two groups with post treatment nausea, vomiting, fever or other complications. 
No significant difference in partial or complete response between the two groups. 
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eluting embolic beads. Currently, there are three commercially 
available, but without FDA indications, DEB-TACE (Oncozene®, 
DC/LC Beads® and QuadraSpheres®) in the U.S. These are being 
used for chemoembolization of liver cancer. The beads are loaded 
with a drug solution, doxorubicin being the most commonly used 
chemotherapeutic agent so that the drug is “trapped” or 
“attached” within the beads during delivery. The rate of drug 
elution (drug release kinetics) from the beads when delivered to 
the desired site varies based on the osmolarity of the tumor bed, 
concentration of the drug, and size of the beads. In vivo studies in 
animal tumor models showed a 400% increase in intra-tumoral 
doxorubicin at 72 hours post injection using DEB-TACE when 
compared with cTACE.16 Consequently, tumor necrosis is more 
profound.16,17 Peripheral blood levels of these chemotherapeutic 
drugs were also found to be significantly lower as compared with 
cTACE, which should result in reduced systemic toxicity.18 
A study by Varela, et al.18, in 27 Child-Pugh A patients treated 
with two rounds of DEB-TACE showed preliminary data on surviv-
al rates of 1 year, 92.5% and 2 years, 88.9%. Average drug con-
centrations in peripheral blood were lower than cTACE, though 
these values did not reach statistical significance.18 This reduced 
systemic toxicity may allow for even higher doses of intra-tumoral 
chemotherapy as repeated locoregional treatment is feasible. 
Contrast uptake on dynamic CT demonstrated a significantly 
higher tumor response rate after DEB-TACE therapy than cTACE 
with 44.4% partial responses, 25.9% stable disease and a total 
of 66.6% objective response.18 The PRECISION V study of 212 pa-
tients with HCC treated with either doxorubicin loaded DEB-TACE 
or cTACE, found higher rates of complete response (27% vs 22%), 
objective response (52% vs 44%) and disease control (63% vs 
52%) respectively.19 A significant increase in objective response 
(P=0.038) was noted in patients with Child-Pugh B, ECOG 1, bi-
lobar disease and recurrent disease of DEB-TACE compared to 
cTACE. In a study with 177 patients of which 89 received DEB-
TACE (doxorubicin coated drug eluting bead TACE) and 88 re-
ceived cTACE, post procedural pain was more frequent and severe 
after cTACE (P<0.001).20 No significant difference was found in 
the local or overall tumor response, time to progression, 1-year 
survival or 2-year survival between the two groups. In a single 
center series of 249 patients with early or intermediate HCC, the 
objective response rate was significantly higher (P=0.039) with 
cTACE (85.3%) compared to DEB-TACE (74.8%), and the median 
time to progression was longer (17 months vs 11 months).21 No 
significant difference was noted in median survival between the 
two groups (39 months vs 32 months), however cTACE demon-
strated a significant survival advantage in patients with bilobar 
neoplasia, portal hypertension and elevated alpha-fetoprotein 
levels. 
TAE
Bland embolization can also be performed without chemother-
apy, known as TAE, relying solely on ischemia-induced effects on 
tumor. TAE without tumoricidal agents may cause ischemia, theo-
retically triggering peritumoral angiogenesis and paradoxical tu-
mor growth and metastatic spread.22 A case controlled retrospec-
tive study which compared patients who received TACE or TAE 
found no significant differences in 3 year survival (TAE 78%, 
TACE 74%, P=0.66), Model for End-Stage Liver Disease score 
and liver transplant waiting time between the two groups.23 TAE 
patients required less repeat procedures (16%) compared to TACE 
patients (40%). In a nationwide cohort study of 405 patients24, 
of which 7.9% underwent TAE and the remaining patients re-
ceived TACE as first line treatment for HCC, no difference in me-
dian survival was found (TACE 20.1 versus TAE 23.1 months, log-
rank P=0.84). In 101 patients with Barcelona Clinic Liver Cancer 
Stage A (22%), or Stage B or C (78%), of which 51 received TAE 
with microspheres alone and 50 received DEB-TACE with doxoru-
bicin 150mg, no significant difference was found in RECIST re-
sponse, adverse events, progression free survival or overall sur-
vival (Table 2).25 
90Y RADIOEMBOLIZATION OR SIRT
Radiation therapy has been used in cancer treatment for more 
than 100 years since the discovery of the x-ray by Roentgen in 
1895. However, it is impossible to achieve a tumoricidal radiation 
dose of greater than 120 Gy to focal tumor of the liver without 
severe complications including liver failure and other fatal GI 
symptoms.26 A new concept of locoregional radiation treatment 
has been developed and was introduced in 1963 with the inten-
tion of effectively treating tumors while minimizing complications 
associated with radiation.27 More than 5000 patients have been 
treated with 90Y since it’s first medical use in 195628,29 and the 
first 90Y radioembolization treatment was performed in colorectal 
hepatic metastases in 1964.30 
Radioembolization or SIRT is an emerging treatment option for 
unresectable primary HCC and colorectal hepatic metastases. 90Y 
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is produced by beta decay and co-exists in equilibrium with its 
parent isotope Strontium 90 (90Sr). It emits characteristic positron 
(β-particle) radiation via beta decay with a half-life of 64.1 hours 
and penetrability of 2.5 mm in soft tissue. Just like in TACE, radio-
embolization is developed with the concept of utilizing the hepatic 
arterial flow to the tumor bring the treatment to the malignancy. 
This results in 90Y microspheres being preferentially and focally 
collected within and close proximity to the tumor. This advantage 
preserves adjacent normal hepatic tissues which are more prefer-
entially supplied by branches of the portal venous system.
Currently, two radioembolization agents are available globally: 
SIR-Spheres® and Thera-Spheres®. SIR-Spheres (Sirtex Medical, 
Wilmington, MA, USA), made of resin or polymer beads, are US 
FDA approved for the transarterial treatment of hepatic metasta-
ses from colorectal cancer. SIR-Sphere with a size of 20-60 μm 
has a higher embolic potential than Thera-Spheres (a size of 25-
35 μm). Each dose per vial contains 40-80 million microspheres 
with a maximal dose of up to 3 GBq. Thera-Spheres (BTG Medical, 
Ottawa, Canada), made of insoluble glass, are US FDA HDE (Hu-
manitarian Device Exemption) approved for the transarterial treat-
ment of unresectable HCC. Each dose per vial contains 1.2-8 mil-
lion microspheres with a maximal dose of 20 GBq.
Recent studies have shown that radioembolization is effective 
in the treatment of unresectable primary HCC and colorectal he-
patic metastasis.26,31-35 Studies performed in the US done by Ken-
nedy, et al., and Salem, et al. have demonstrated a median sur-
vival of 10.5 months35 and 12.5 months32 respectively, which is 
comparable to an Australian study with mean survival of 15 
months31 and 9.4 months in an Asian study.36 In addition to sur-
vival data, Kulik, et al. have demonstrated potential down-staging 
of HCC with Thera-Spheres to T2 tumor staging status, which may 
provide the potential for surgical treatments, including OLT.37 An-
other important aspect of radioembolization includes the tumori-
cidal effect of radiombolization which may provide symptomatic 
improvement of cancer patients due to decreased tumor burden. 
As with other tumoricidal therapeutic treatments, several side ef-
fects have been reported including direct radiation effects and se-
vere gastrointestinal toxicities.38 These side effects are likely due 
to variant or collateral circulation which allows radioembolic ma-
terial to be deposited in undesired locations.
Comparison of 179 patients with Barcelona Clinic Liver Cancer 
stage A or B demonstrated a significantly longer median time to 
progression in patients who received 90Y than cTACE (>26 months 
vs 6.8 months, P =0.007) and increased diarrhea (21 vs 0%, 
P=0.031) and hypoalbuminemia (58% vs 4%, P<0.001) was not-
ed in the cTACE group compared to the 90Y group.39 No difference 
in the median survival time was found between the two groups. 
In a large meta-analysis of 553 patients with unresectable HCC, 
284 underwent TACE and 269 underwent transaterial radioembo-
lization.40 TACE required longer hospital stay (P<0.01) and had 
more post treatment pain (P<0.01), but less subjective fatigue 
compared to transarterial radioembolization. No significant differ-
ence in survival up to 4 years, post treatment nausea, vomiting, 
fever, partial or complete response was found between the two 
groups (Table 3).
Two current clinical trials for SIR-Spheres in the US are currently 
being conducted.10 These randomized clinical trials will provide 
further insights into re which appears promising in its preliminary 
results in treating hepatic malignancies.
THE FUTURE OF TRANS-ARTERIAL EMBOLIZA-
TION THERAPY
Trans-arterial embolization therapy has become a widely utilized 
therapeutic option for patients with advanced hepatic malignan-
cies who cannot be effectively treated with surgical resection or 
ablative methods. Although Trans-arterial embolization therapy 
has been shown to be effective in prolonging survival and result-
ed in tumor response in those patients with advanced diseases, 
further investigation to better understand its pathophysiology, 
toxicology/side-effects, immunological responses and genomic 
and proteomic changes, are crucial to improve efficacy, patient 
tolerability and survival benefit after Trans-arterial embolization 
therapy. 
Systemic chemotherapeutic treatment of HCC has been shown 
to have little to no effect on patient survival or palliation. Howev-
er, implementing newer chemotherapeutic agents, especially tar-
geting angiogenesis, into locoregional chemoembolization may 
further benefit patient survival and may have synergistic tumori-
cidal effect when concomitantly used with current agents. These 
agents include Bevacizumab (Avastin®, monoclononal anti-VEGFR 
antibody), Sorefanib (Nexavar®, tyrosine kinase antagonist), Erlo-
tinib (Tarceva®, EGFR tyrosine kinase inhibitor), and Panitumumab 
(Vectibix®, monoclononal anti-EGFR antibody). In 2008, the 
SHARP trial in over 300 patients with advanced HCC has demon-
strated the survival benefit of Sorefanib with the median overall 
survival of 10.7 months compared to the placebo group with 7.9 
months (P<0.001).41
In conclusion, attention should be given to newer technologies 
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for early diagnosis of cancer, genetic and subcellular analysis of 
cancer, monitoring of cancer progression and post-treatment pro-
gression which ultimately determines patient survival and the ef-
fectiveness of treatments. Modern technologies including micro-
array gene expression profiling, proteomic data, molecular 
imaging and newer diagnostic/functional imaging, which will be 
incorporated with chemoembolization treatment regimens. These 
technologies should provide extensive and novel information on 
cellular and molecular level events which dictates the outcome of 
hepatic malignancy. In addition, we will be able to understand in-
dividual differences in treatment response and identify novel and 
personalized diagnostic and therapeutic regimens for hepatic ma-
lignancies. 
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